Skip to content
MARKETS / NASDAQ / QNTM
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Quantum Biopharma Ltd. QNTM

5 fiscal years on record · USD · FY2022 reported · SEC filings only
$-23.6M
$-28.4M
In brief

What this company does

The Company has also licensed unbuzzd™, a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption, to Unbuzzd and Celly U.S., and is entitled to a royalty on the revenue generated by Unbuzzd and Celly U.S. from sales of products created using the technology rights granted under the Unbuzzd IP License Agreement. Finally, the Company has expanded its corporate treasury management function to include investments in cryptocurrencies. unbuzzd™ is a consumer recreational beverage product that will be sold via retail distribution.

Written from the business description in Quantum BioPharma Ltd.'s annual report to the U.S. Securities and Exchange Commission, filed 26 March 2026. Every sentence was checked against that document before publication.

Growth
Revenue, FY2022 · full 5-year series below
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
ROE

Not available in our data for this period.

Each USD of equity lost 77 cents this year.

Cash & shareholders
returned in FY2022 · dividends + net buybacks
Free cash flow $M
FY2022 · FCF -28.4
-10M-20M20182019202020212022

Total assetsUSD 38.4M
EquityUSD 30.5M
CashUSD 17.0M
Current ratio2.28×

Equity funds 80% of total assets.

The 5-year record
5 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20222021202020192018
Revenue CAD B···0.0·
Operating income $B−0.0−0.0−0.0−0.0·
EBITDA $B−0.0−0.0−0.0−0.0−0.0
Income tax $B·····
Net income $B−0.0−0.0−0.0−0.0·
Free cash flow $B−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.69−0.97−2.36··
Dividend / sh $·····
Payout %·····
ROE %−77.3····

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 2 failures · 1 divergences in 28 reconciliationsAUDITED

Reconciled in 6 of 19 fiscal years. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 67 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente2 failures1 divergent
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code A6
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2018

Share this section

Download image